亞盛醫藥-B(06855.HK)治療淋巴瘤藥物獲內地臨床試驗許可
亞盛醫藥-B(06855.HK)公布,其關鍵候選產品Bcl-2選擇性抑制劑APG-2575(Lisaftoclax)獲國家藥監局(NMPA)藥物審評中心(CDE)臨床試驗許可,將開展其聯合布魯頓酪氨酸激(酉每)(BTK)抑制劑阿可替尼對比免疫化療治療的全球關鍵註冊性III期臨床研究,用於初治慢性淋巴細胞白血病/小淋巴細胞淋巴瘤(CLL/SLL)患者一線治療。
該研究是一項全球多中心、隨機對照、開放性的關鍵註冊性III期臨床研究(APG2575CC301),旨在評估APG-2575(Lisaftoclax)聯合阿可替尼對比免疫化療治療初治CLL/SLL患者的有效性及安全性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.